Celgene’s Velcade (bortezomib), Revlimid (lenalidomide) and Darzalex (daratumumab) and dexamethasone plus with low dose cyclophosphamide, and in conjunction with an autologous stem cell transplant.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Rituximab and cyclophosphamide are equally effective in achieving remission or low disease activity rates in childhood-onset antineutrophil cytoplasmic antibody–associated vasculitis (AAV), and ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM). The drugmaker ...

A genetic regulator of tomato sweetness has been identified through comparison of wild and domesticated varieties of the plant. Genetically engineering tomatoes to alter this gene increases sugar ...

Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa (isatuximab) combo therapy for relapsed or refractory multiple myeloma. The ...

I would consider daratumumab [Darzalex] with lenalidomide [Revlimid], bortezomib [Velcade], and dexamethasone [D-RVd] for her. We can talk a bit further about those studies in a moment. Dr Braunstein, ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. The study is testing the drug in certain patients ...